Corporate | 16 May 2012 07:28
Evotec AG / Key word(s): Miscellaneous
16.05.2012 / 07:28
---------------------------------------------------------------------
Hamburg, Germany - 16 May 2012: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX) is proud to announce the addition of Agilent Technologies' RapidFire
Mass Spectrometry analysis capabilities to their High Throughput Screening
facilities in Hamburg.
RapidFire, a robust, in-line solid phase extraction technology enables
ultrafast, direct analysis of native compounds for a wide variety of
biochemical assays including routine ADME and lead discovery applications
across a range of therapeutic areas. Evotec is the first Pharmaceutical
Contract Research Organisation in Europe to offer these services. The Evotec
facility in Hamburg will be equipped with state-of-the-art technology from
Agilent including multiple RapidFire High-throughput Mass Spectrometry
Systems and 6460 Triple Quadrupole instrumentation.
'Evotec is the ideal partner for Agilent Technologies as we expand this
industry-leading platform into the European Contract Research market,' said
Gustavo Salem, Agilent Vice President and General Manager, Biological
Systems Division. 'Evotec's leadership role as a drug discovery service
provider will ensure that this market is exposed to the capabilities of
Agilent's RapidFire and gold-standard Mass Spectrometry platforms.'
Mario Polywka, Chief Operating Officer for Evotec commented: 'The addition
of Agilent's RapidFire Mass Spectrometry analysis instrumentation and
capabilities is a tremendous boost to Evotec's best in class screening
platform. Working with Agilent will ensure that these systems are brought
into operation quickly and that our partners and collaborators will benefit
from further efficiencies in lead discovery.'
Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler@evotec.com
FORWARD LOOKING STATEMENTS - Information set forth in this press
release contains forward-looking statements, which involve a number of risks
and uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a variety
of risks and uncertainties, many of which are beyond our control, and which
could cause actual results to differ materially from those contemplated in
these forward-looking statements. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any such
statements to reflect any change in our expectations or any change in
events, conditions or circumstances on which any such statement is based.
End of Corporate News
---------------------------------------------------------------------
16.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
170170 16.05.2012